Karyopharm appoints Lori Macomber as CFO effective Jan 3, 2025

Karyopharm Therapeutics Inc.

Macomber previously CFO at Legend Biotech, will serve as EVP, CFO and Treasurer.
Annual base salary of $475,000; target annual bonus of 45% of base salary.
Inducement equity: option for 650,000 shares and 160,000 RSUs, vesting over 4 and 3 years.
Kristin Abate, interim principal financial officer, will step down on Jan 3, 2025.
Severance includes one month base salary per month of service (max 12 months), enhanced upon change in control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.